pH敏感型K5多糖-阿霉素前体药物的制备及其性能
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Preparation and Property Study of the pH-Sensitive K5 Polysaccharide-Doxorubicin Prodrug
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    利用肝素前体K5多糖,通过腙键(Hydrazone bond)连接抗肿瘤药物阿霉素(DOX),制备具有pH敏感性的K5-hydrazone-DOX(KHD)前体药物。对其载药量、形貌和体外药物释放等性质进行了研究,并通过HeLa细胞对其体外细胞毒性和细胞摄取进行了评价。结果表明,所制备的KHD前体药物中,DOX质量分数为18.0%。药物释放结果显示,KHD前体药物在pH 5.0条件下对DOX的释放率远高于pH 7.4条件下的释放率,具有明显的pH响应性。细胞实验表明,KHD前体药物可迅速被细胞摄取,并且具有肿瘤细胞抑制作用。本研究结果表明,KHD是一种有潜在应用价值的抗肿瘤前体药物。

    Abstract:

    In this study, K5 polysaccharide (heparosan) was conjugated with anticancer drug DOX via hydrazone bond to obtain pH-sensitive K5-hydrazone-DOX (KHD) prodrug. The drug loaded capacity, morphology, and in vitro drug release were investigated. Its in vitro cytotoxicity and cellular uptake against HeLa cells were also evaluated. The results showed that the DOX content of KHD is 18.0%. The release rate of DOX at pH 5.0 was much faster than that at pH 7.4, revealing a pH-triggered release manner. The KHD prodrug could achieve intracellular delivery and showed effective cytotoxicity in vitro. This study indicates that the KHD prodrug may be a potential candidate for cancer therapy.

    参考文献
    相似文献
    引证文献
引用本文

刘文,张苗,陈荆晓,陈敬华. pH敏感型K5多糖-阿霉素前体药物的制备及其性能[J].食品与生物技术学报,2015,34(6):634-639.

LIU Wen, ZHANG Miao, CHEN Jingxiao, CHEN Jinghua. Preparation and Property Study of the pH-Sensitive K5 Polysaccharide-Doxorubicin Prodrug[J]. Journal of Food Science and Biotechnology,2015,34(6):634-639.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2015-08-09
  • 出版日期:

版权所有:《食品与生物技术学报》编辑部

地址:江苏省无锡市蠡湖大道1800号  邮政编码:214122

电话:0510-85913526  电子邮件:xbbjb@jiangnan.edu.cn

技术支持:北京勤云科技发展有限公司

微信公众号二维码

手机版网站二维码